Prostate Cancer: New Urine Test May Help Reduce Unnecessary Biopsies

Why prostate biopsies are so common (and why that’s a problem)

In the U.S., prostate cancer is incredibly commonyet it’s also a “wide personality” disease. Some tumors are slow-growing
and may never cause harm. Others are aggressive and need fast action. The challenge is sorting those two groups early,
before anyone gets unnecessary proceduresor worse, misses a dangerous cancer.

The PSA test is an alarm system, not a diagnosis

The prostate-specific antigen (PSA) blood test is often the first step. PSA can rise when cancer is presentbut it can
also rise for non-cancer reasons like benign prostatic hyperplasia (BPH), inflammation, infection, recent ejaculation,
cycling, or simply having more birthdays than you’d like to count.

That’s the core problem: PSA is sensitive, but not specific. An elevated PSA can trigger a chain reactionrepeat labs,
referrals, imaging, and sometimes a biopsyeven when no clinically important cancer is there.

Biopsies help diagnose cancer, but they’re still invasive

A prostate biopsy typically involves taking multiple tissue samples using a needle (often guided by ultrasound, sometimes
guided by MRI findings). It’s usually outpatient, and many people do finebut “fine” can still include discomfort, bleeding,
urinary symptoms, and infection risk. Even when complications are uncommon, they’re not imaginary.

There’s also the emotional side: waiting for results, imagining worst-case scenarios, and then learning the biopsy was
negative (relief!)but also wondering why you had to go through all of that in the first place.

What clinicians really want: better risk sorting before the biopsy

Modern prostate cancer detection is moving away from the old “PSA is high, everybody gets biopsied” era. Today, many
clinicians use a layered approach: PSA trends over time, personal risk factors, digital rectal exam (sometimes), MRI,
and biomarker tests from blood or urine.

Biomarker tests are basically a smarter “second opinion.” Instead of relying on PSA alone, they look for patterns linked
more specifically to clinically significant prostate cancerthe kinds more likely to matter.

Urine tests aren’t brand-newso what’s different now?

Urine-based biomarker testing has been around for a while, including tests that measure PCA3 or other gene signals.
Some options also analyze exosomes (tiny biological “packages” carrying RNA) shed by prostate cells. The big idea is the same:
detect molecular hints of higher-grade disease without cutting anyone open.

What’s exciting about the newer generation is improved accuracy for identifying clinically significant cancers
(often defined as Grade Group 2 or higher). That focus matters because it aims to reduce two things at once:
unnecessary biopsies and overdiagnosis of low-risk cancer.

Meet the newer test: MyProstateScore 2.0 (MPS2)

One of the most talked-about “new urine tests” is MyProstateScore 2.0 (MPS2), an 18-gene urine-based assay.
It builds on earlier urine biomarker work (including the original MyProstateScore) by expanding the gene panel to better
flag higher-grade cancers.

What it measures, in plain English

MPS2 analyzes gene signals found in urine that are associated with prostate cancer biologyespecially signals that show up
more often when the cancer is likely to be clinically significant. The output is a risk estimate that helps inform the next step:
proceed to MRI and/or biopsy, or consider continued monitoring and shared decision-making.

A practical upgrade: no digital rectal exam required for collection

Traditionally, some urine biomarker tests have been collected after a digital rectal exam (DRE) because prostate manipulation
can increase the amount of prostate material in the urine. More recent validation work for MPS2 has focused on
first-catch urine without a DRE, which is a big deal for convenience and access.

Translation: collecting the sample can be simpler, less awkward, and potentially easier to expand into settings where quick,
standardized collection matters.

Where the science comes from

MPS2 development and validation have been tied to major academic and federally supported research efforts, with published results
in leading peer-reviewed medical journals. That doesn’t make it perfectbut it does mean the performance claims aren’t just marketing copy.

How much could it reduce unnecessary biopsies?

Here’s the headline reason people are paying attention: in published validation data, MPS2 was associated with avoiding a meaningful share
of biopsies while maintaining strong sensitivity for higher-grade cancer.

What the numbers mean in real life

In one clinical validation cohort (men being evaluated for biopsy), a testing strategy designed to detect more than 90% of Grade Group ≥2 cancers
suggested MPS2 could avoid roughly about one-third to over 40% of unnecessary biopsies in the initial biopsy setting.
In men with a prior negative biopsy, estimates were even higher for avoiding repeat biopsies.

A simple example (because percentages are easier with coffee)

Imagine 100 men with elevated PSA who are anxious, googling at midnight, and scheduled for a biopsy “just to be safe.”
If a urine biomarker test helps identify 35 to 45 of them as low risk for clinically significant cancer, those men might be able to:

• avoid an immediate biopsy,
• avoid biopsy-related complications,
• reduce unnecessary MRI use in some scenarios,
• and focus on monitoring PSA trends and symptoms with their clinician.

Meanwhile, the test is designed so the men at higher risk still move forward with MRI and/or biopsybecause “avoid biopsies”
should never mean “ignore dangerous cancer.”

Where a urine test fits in the modern prostate-cancer workup

Think of prostate cancer detection like airport security (stay with me): PSA is the metal detector. It catches a lot of things,
including belt buckles. A urine biomarker test is like the follow-up scanner that helps decide who truly needs the pat-down.
The goal is fewer unnecessary pat-downswithout letting real threats stroll through.

A realistic pathway many clinics follow

1. PSA test (and often a repeat PSA) to confirm it wasn’t a temporary spike.
2. Risk review: age, family history, race/ethnicity, urinary symptoms, medications, prior biopsy, PSA density, PSA velocity.
3. Secondary testing: urine or blood biomarkers and/or multiparametric MRI (mpMRI), depending on availability and patient preference.
4. Biopsy if risk remains significantespecially if MRI is suspicious or biomarkers suggest higher-grade disease.

What about MRIdoes the urine test replace it?

Not exactly. mpMRI can be extremely helpful, especially for targeting suspicious lesions. But MRI access and quality can vary, interpretation can
be subjective, and not every patient can get an MRI quickly (or at all). A urine test can help refine risk earlier and may reduce
the number of people who need MRI or biopsy right away.

Who might benefit most from the newer urine test?

A urine biomarker test like MPS2 is typically most relevant for people who are in the “gray zone”not clearly low risk, not obviously high risk,
and staring down the decision to biopsy.

Common scenarios where it could help

• Elevated PSA with no clear explanation (and especially if the PSA is confirmed on repeat testing).
• Borderline risk where the clinician and patient want more objective data before biopsy.
• Prior negative biopsy but ongoing concern (repeat biopsies are not anyone’s favorite hobby).
• Limited MRI access or situations where MRI delays would stall decision-making.
• Preference-sensitive decisions where a patient values avoiding invasive testing unless the risk is truly meaningful.

When a urine test should not be the “only” deciding factor

If someone has a very suspicious MRI, a strongly abnormal digital rectal exam, rapidly rising PSA, or other high-risk features,
clinicians may still recommend biopsy regardless of a biomarker result. Biomarkers support decisionsthey don’t replace clinical judgment.

Limitations (because every good tool comes with fine print)

The most responsible way to talk about new tests is to include what we still don’t know.

Diversity and real-world performance

Some study cohorts have had limited representation of certain racial and ethnic groups, including Black menwho face higher prostate cancer risk and
worse outcomes in the U.S. That means broader validation is important to confirm performance across populations and reduce inequities, not accidentally
widen them.

No test is perfect

Even highly sensitive tests can miss cases. The goal is to miss as few clinically significant cancers as possible while meaningfully reducing
unnecessary biopsies. That balance is why clinicians often combine biomarkers with PSA patterns, imaging, and follow-up plans instead of using
a single result in isolation.

Access, insurance, and logistics

Coverage can vary. Some biomarker tests become widely used quickly; others take time to integrate into guidelines and payer policies.
The best approach is to ask your clinician whether the test is available in your area, what it costs, and how the results will change your plan.

Questions to ask your clinician (to make the visit productive, not just expensive)

• Is my PSA result confirmed with a repeat test, and what might be influencing it?
• What is my estimated risk of clinically significant prostate cancer based on my overall profile?
• Would a urine biomarker test like MPS2 be appropriate before MRI or biopsy?
• If I get the test, what result would lead us to biopsyand what result would lead to monitoring?
• How will we follow up if we defer biopsy (timeline, repeat PSA, MRI, symptoms to watch)?
• What are the risks of biopsy for me personally (including infection risk and bleeding risk)?

The bottom line

A newer urine biomarker test such as MPS2 represents a promising shift: smarter risk assessment for men with elevated PSA,
fewer unnecessary biopsies, and more focus on detecting the cancers that actually need treatment. It’s not a magic wand,
and it doesn’t eliminate the need for MRI or biopsy in everyonebut it may help turn prostate cancer screening into a more
personalized, less invasive process.

Experiences: What this urine-test approach can feel like in real life (about )

The science is importantbut so is the human experience of living inside the decision. Below are composite, realistic scenarios
(not specific real patients) that reflect the kinds of stories urology clinics hear every day.

1) “My PSA is up… now what?”

Marcus is 58, healthy, and the kind of guy who actually uses the annual physical as an annual physical (rare species).
His PSA comes back higher than last year. He feels fine. No pain, no dramatic symptomsjust a number on a lab report that
suddenly has him spiraling at 2 a.m.

In the past, the path might have been fast: elevated PSA → schedule biopsy. Instead, his clinician repeats the PSA to confirm
it wasn’t a temporary bump, reviews factors that can nudge PSA upward, and talks through options. A urine biomarker test becomes
part of the conversationnot as a “get out of jail free” card, but as a way to better answer Marcus’s real question:
“What’s the chance I have the kind of cancer that needs action?”

When his urine test suggests low likelihood of clinically significant cancer, Marcus doesn’t feel like he “won”he feels like
he has a plan. Monitoring no longer sounds like doing nothing. It sounds like doing something thoughtful.

2) The repeat-biopsy dread

David is 64 and already had one biopsy two years ago after an elevated PSA. It was negative. Great newsexcept his PSA stayed high,
and now it’s creeping upward again. The first biopsy wasn’t traumatic, but it wasn’t exactly a spa day. He remembers the antibiotics,
the discomfort, the worry, and the waiting.

A urine test in this repeat-biopsy setting can be especially meaningful because the stakes feel different. David isn’t just afraid of
cancer; he’s afraid of an endless loop of procedures. When a biomarker test suggests higher risk, the decision to do MRI and/or biopsy feels
more justified and less like déjà vu. When it suggests lower risk, David and his clinician can discuss whether close follow-up is reasonable
rather than jumping straight into another round of needles.

3) Access and the “MRI gap”

Anthony lives hours from a major medical center. In his community, getting a high-quality mpMRI quickly isn’t always realistic.
Appointments can take weeks, and travel time adds cost and stress. In these settings, a urine biomarker test isn’t just convenientit can be
a bridge. It helps prioritize who needs urgent imaging and specialist care, and who can safely monitor while waiting for the next step.

4) The emotional math of “watching and waiting”

For many people, the hardest part isn’t the testit’s the uncertainty. A urine biomarker result doesn’t erase fear, but it can shrink the unknown.
It gives patients a clearer “why” behind the plan. Instead of “We’re not doing a biopsy because we hope it’s fine,” the message becomes:
“We’re not doing a biopsy right now because the data suggests low risk of the cancers that typically require treatment, and we’ll keep checking.”

That differencehope versus evidencecan be the difference between feeling dismissed and feeling cared for.